AFT Pharmaceuticals Ltd AFT
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- NZD 3.06
- Day Range
- NZD 3.06–3.06
- 52-Week Range
- NZD 2.84–3.92
- Bid/Ask
- NZD 3.10 / NZD 3.14
- Market Cap
- NZD 320.89 Mil
- Volume/Avg
- 95 / 23,240
Key Statistics
- Price/Earnings (Normalized)
- 29.16
- Price/Sales
- 1.85
- Dividend Yield (Trailing)
- 0.36%
- Dividend Yield (Forward)
- 0.36%
- Total Yield
- 0.36%
Company Profile
AFT Pharmaceuticals Ltd is a pharmaceutical distributor and developer of pharmaceutical intellectual property. Some of the products of the organization are Aqueous cream, Calci-tab, Maxigesic, Cromo-fresh, Crystaderm, Crytawash, Ellgy plus, Emulsifying ointment, and others. The group has four operating segments based on geographical location being, Australia, New Zealand, Asia, and the Rest of the world. It generates the majority of the revenue from Australia which includes the sales and distribution activity relating to the Australian market.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Stock Style Box
- Small Growth
- Total Number of Employees
- 97
- Website
- https://www.aftpharm.com
Comparables
Valuation
|
Metric
|
AFT
|
FBU
|
HLG
|
|---|---|---|---|
Price/Earnings (Normalized) | 29.16 | 18.76 | 10.87 |
Price/Book Value | 4.34 | 0.92 | 3.59 |
Price/Sales | 1.85 | 0.38 | 0.85 |
Price/Cash Flow | 33.26 | 6.91 | 5.09 |
Price/Earnings
AFT
FBU
HLG
Financial Strength
|
Metric
|
AFT
|
FBU
|
HLG
|
|---|---|---|---|
Quick Ratio | 0.82 | 0.64 | 0.60 |
Current Ratio | 1.97 | 1.69 | 1.29 |
Interest Coverage | 5.61 | 0.39 | 13.44 |
Quick Ratio
AFT
FBU
HLG
Profitability
|
Metric
|
AFT
|
FBU
|
HLG
|
|---|---|---|---|
Return on Assets (Normalized) | 8.04% | 0.40% | 15.61% |
Return on Equity (Normalized) | 16.95% | 1.02% | 33.99% |
Return on Invested Capital (Normalized) | 12.67% | 0.46% | 19.65% |
Return on Assets
AFT
FBU
HLG
Drug Manufacturers - Specialty & Generic Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
MKKGY
| Merck KGaA ADR | Qlfvhvybw | Lmnyzr | $70.5 Bil | |
ZTS
| Zoetis Inc Class A | Fsshrbqzg | Bdk | $70.0 Bil | |
HLN
| Haleon PLC ADR | Hjdygqb | Pbfbc | $36.3 Bil | |
TEVA
| Teva Pharmaceutical Industries Ltd ADR | Cxgmmdpcm | Cxst | $14.3 Bil | |
VTRS
| Viatris Inc | Tvwlrgwk | Pgyx | $13.2 Bil | |
RDY
| Dr Reddy's Laboratories Ltd ADR | Tqlqdqzl | Kpghn | $12.0 Bil | |
CTLT
| Catalent Inc | Ppdwygg | Ftvqxz | $10.1 Bil | |
PRGO
| Perrigo Co PLC | Yzskqpyx | Hcpc | $4.1 Bil | |
CURLF
| Curaleaf Holdings Inc | Pndylpfd | Rwb | $3.7 Bil | |
PBH
| Prestige Consumer Healthcare Inc | Nvrsrblx | Sjkgxk | $3.4 Bil |